Category Archives: Press Release

OPKO Health’s 4Kscore® Test Highlighted in Podium Presentation at 112th American Urological Association Annual Meeting

MIAMI, May 18, 2017 (GLOBE NEWSWIRE) — OPKO Health, Inc.(NASDAQ:OPK), announces that data from a prospective study conducted at Veteran Affairs (VA) hospitals confirming the 4Kscore test’s ability to accurately predict aggressive prostate cancer were presented in a podium presentation on May 16, 2017 at the 112thAmerican Urological Association (AUA) Annual Meeting in Boston. The study entitled, “An Independent, Multi-Institutional, Prospective […]

OPKO Subsidiary GenPath Women’s Health Announces the Availability of ClariTest™

MIAMI, March 07, 2017 (GLOBE NEWSWIRE) — OPKO Health, Inc. (NASDAQ:OPK) announces that GenPath Women’s Health, a business unit of OPKO Health subsidiary BioReference Laboratories, will offer ClariTest™, a non-invasive prenatal test (NIPT) initially to be performed at Illumina, Inc. (NASDAQ:ILMN) on the Verifi™ platform.  This platform utilizes massively parallel sequencing technology to screen for trisomies 13, 18, 21 and sex chromosome abnormalities, with […]

OPKO Health Appoints Jane Pine Wood as Chief Legal and Compliance Officer of BioReference Laboratories

MIAMI–(BUSINESS WIRE)– OPKO Health, Inc. (Nasdaq: OPK) announces the appointment of Jane Pine Wood, Esq. as Chief Legal and Compliance Officer of its wholly owned subsidiary, BioReference Laboratories, effective October 1, 2016. Ms. Wood is a nationally respected healthcare attorney who has been practicing law for 29 years. She specializes in laboratory regulatory and compliance matters, and has counseled more than 500 […]

OPKO to Discuss Draft Coverage Determinations for 4Kscore® Test at 2016 Jefferies Healthcare Conference

MIAMI–(BUSINESS WIRE)– OPKO Health, Inc. (NYSE: OPK) today announced that senior management will discuss recent draft local coverage determinations by certain Medicare Administrative Contractors for OPKO’s 4Kscore® test at the Jefferies Healthcare Conference in New York City on Thursday, June 9, 2016 at 11:30 AM (EDT). OPKO previously announced that Novitas Solutions issued a positive draft local coverage determination proposing to establish reimbursement coverage for patients with PSA […]

OPKO Health Receives Proposed/Draft Medicare Local Coverage Determination for 4Kscore® Test

MIAMI–(BUSINESS WIRE)– OPKO Health, Inc. (NYSE:OPK) (“OPKO” or the “Company”) announces that Novitas Solutions has issued a draft local coverage determination for the 4Kscore® Test, the only blood test that accurately identifies an individual patient’s risk for high-grade, aggressive prostate cancer. Novitas Solutions is a Medicare Administrative Contractor (MAC) for Medicare jurisdictions L and H, with responsibility for nearly 10 million Medicare beneficiaries in New […]

OPKO Health Names Dr. Gregory Henderson President of Bio-Reference Laboratories

MIAMI–(BUSINESS WIRE)– OPKO Health, Inc. (NYSE: OPK) announces the appointment of Gregory Henderson, M.D., Ph.D., as President of BioReference Laboratories (BRL), effective immediately. Dr. Henderson succeeds Marc Grodman, M.D., who is resigning, having served as Chairman, President and CEO of BRL since founding the company in 1981. OPKO acquired BRL in August 2015. Dr. Grodman […]

OPKO 4Kscore® Recommended in 2016 European Association of Urology Prostate Cancer Guidelines

MIAMI–(BUSINESS WIRE)– OPKO Health, Inc. (NYSE:OPK) today announced the decision of the European Association of Urology (EAU) Prostate Cancer Guidelines Panel to include the 4Kscore® Test in the 2016 EAU Guidelines for Prostate Cancer. The panel concluded that the 4Kscore, as a blood test with greater specificity over the PSA test, is indicated for use prior to a first prostate biopsy […]

Study Demonstrates OPKO’s 4Kscore Test Reduces Unnecessary Prostate Biopsies While Improving Risk Prediction for Aggressive Prostate Cancer

4Kscore Test Results Significantly Influenced Physician-Patient Shared Decision-Making in Clinical Practice and Led to a 64.6% Reduction in Prostate Biopsies MIAMI–(BUSINESS WIRE)– OPKO Health, Inc. (NYSE: OPK) announced today the results of a study for the 4Kscore® Test’s clinical utility in reducing the number of prostate biopsies performed, while increasing the probability of detecting aggressive prostate cancer […]

OPKO 4Kscore Test Receives Category I CPT Code Approval

MIAMI–(BUSINESS WIRE)– OPKO Health, Inc. (NYSE:OPK) announced today that the American Medical Association (AMA) Current Procedural Terminology (CPT®) Editorial Panel has granted a Category I CPT code for its 4Kscore® Test, the only blood test that accurately identifies an individual patient’s risk for aggressive prostate cancer. This important event upgrades the 4Kscore Test from a Category III Administrative code to a […]

OPKO Health Refinances Bio-Reference Laboratories Credit Facility

MIAMI–(BUSINESS WIRE)– OPKO Health, Inc. (NYSE:OPK) today announced today that it has successfully closed on a new five-year $175.0 million secured revolving credit facility with JPMorgan Chase. The new facility replaced Bio-Reference Laboratories’ previous $120.0 million secured revolving credit facility. “We are excited to enter into a partnership with one of the world’s premier banking institutions, JPMorgan Chase,” commented Phillip Frost, MD, Chairman & […]